343 related articles for article (PubMed ID: 19414193)
1. Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias.
Vercauteren SM; Bashashati A; Wu D; Brinkman RR; Eaves C; Eaves A; Karsan A
Leuk Res; 2009 Dec; 33(12):1636-42. PubMed ID: 19414193
[TBL] [Abstract][Full Text] [Related]
2. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
3. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders.
Lorand-Metze I; Ribeiro E; Lima CS; Batista LS; Metze K
Leuk Res; 2007 Feb; 31(2):147-55. PubMed ID: 16750852
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.
Wimazal F; Fonatsch C; Thalhammer R; Schwarzinger I; Müllauer L; Sperr WR; Bennett JM; Valent P
Leuk Res; 2007 Nov; 31(11):1461-8. PubMed ID: 17507091
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
[TBL] [Abstract][Full Text] [Related]
7. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil.
Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR
Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432
[TBL] [Abstract][Full Text] [Related]
9. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia.
Konoplev S; Medeiros LJ; Lennon PA; Prajapati S; Kanungo A; Lin P
Cancer; 2007 Oct; 110(7):1520-6. PubMed ID: 17701956
[TBL] [Abstract][Full Text] [Related]
10. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.
Valent P; Horny HP
Eur J Clin Invest; 2009 Jul; 39(7):548-53. PubMed ID: 19453651
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric evaluation of proliferative activity and ploidy in myelodysplastic syndromes and acute leukemias.
Riccardi A; Montecucco CM; Danova M; Ucci G; Mazzini G; Giordano PA; Pasquali F
Basic Appl Histochem; 1986; 30(2):181-92. PubMed ID: 2427061
[TBL] [Abstract][Full Text] [Related]
12. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification.
Verburgh E; Achten R; Louw VJ; Brusselmans C; Delforge M; Boogaerts M; Hagemeijer A; Vandenberghe P; Verhoef G
Leukemia; 2007 Apr; 21(4):668-77. PubMed ID: 17301818
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic analysis of myelodysplastic syndromes.
Del Cañizo MC; Fernández ME; López A; Vidriales B; Villarón E; Arroyo JL; Ortuño F; Orfao A; San Miguel JF
Haematologica; 2003 Apr; 88(4):402-7. PubMed ID: 12681967
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary study of biological characteristics of myelodysplastic syndromes clonal cells].
Li X; Wu LY; Ying SX; Chang CK; He Q; Song LQ; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):478-83. PubMed ID: 18072633
[TBL] [Abstract][Full Text] [Related]
15. High incidence of apoptosis in peripheral blood of myelodysplastic syndrome patients determined by Papanicolaou-stained preparations.
Emura I
Lab Hematol; 2003; 9(1):42-6. PubMed ID: 12661827
[TBL] [Abstract][Full Text] [Related]
16. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
17. Conventional cytogenetics and fluorescence in situ hybridization in persistent cytopenias and myelodysplastic syndromes in childhood.
Touliatou V; Kolialexi A; Tsangaris GT; Moschovi M; Polychronopoulou S; Mavrou A
Anticancer Res; 2004; 24(6):3945-9. PubMed ID: 15736436
[TBL] [Abstract][Full Text] [Related]
18. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
[TBL] [Abstract][Full Text] [Related]
19. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of myelodysplastic syndromes in cytopenic patients.
Wang SA
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1085-110, vii. PubMed ID: 22054736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
